IOVANCE BIOTHERAPEUTICS, INC.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
IOVA$8.17+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive Loss
(in thousands)
| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| | Years Ended December 31, | |||||||
| · 2025 · · 2024 · · 2023 | ||||||||
| Net Loss | $(390,978) | | $(372,177) | | $(444,037) | |||
| Other comprehensive loss: | | | | | | |||
| Unrealized gain (loss) on investments | (54) | | 78 | | 940 | |||
| Foreign currency translation adjustment | | 17,540 | | | (3,650) | | | 2,488 |
| Comprehensive Loss | $(373,492) | | $(375,749) | | $(440,609) | |||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.